Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine

Archives of General Psychiatry

Volumn 47, Issue 6, 1990, Pages 577-585

  Goodman, Wayne K ^a   Price, Lawrence H ^a   Delgado, Pedro L ^a   Palumbo, Joseph ^a   Krystal, John H ^a   Nagy, Linda M ^a   Rasmussen, Steven A ^b   Heninger, George R ^a   Charney, Dennis S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; FLUVOXAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPULSION; HUMAN; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANXIETY DISORDERS; BASAL GANGLIA; COMPARATIVE STUDY; DEPRESSIVE DISORDER; DESIPRAMINE; DOPAMINE; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HUMAN; MALE; OBSESSIVE-COMPULSIVE DISORDER; OXIMES; PANIC; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025294010     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1990.01810180077011     Document Type: Article

References (123)

1. Rasmussen SA, Tsuang MT. Epidemiology of obsessive compulsive disorder: a review. J Clin Psychiatry. 1984;45:450-457.
2. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, Regier DA. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41:949-958.
3. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:1094-1099.
4. Renynghe de Voxrie GV. Anafranil (G34586) in obsessive neurosis. Arch Neurol Belg. 1968;68:787-792.
5. Capstick N. Chlorimipramine in obsessional states. Psychosomatics. 1971;12:332-335.
6. Yaryura-Tobias JA, Neziroglu F, Bergman L. Chlorimipramine, for obsessive-compulsive neurosis: an organic approach. Curr Ther Res. 1976;20:541-548.
7. Marks IM, Stern RS, Mawson D, Cobb J, McDonald B. Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry. 1980;136:1-25.
8. Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am J Psychiatry. 1985;142:572-576.
9. Thorén P, Asberg M, Cronholm B, Jornestedt L, Träskman L. Clomipramine treatment of obsessive-compulsive disorder, I: a controlled clinical trial. Arch Gen Psychiatry. 1980;37:1281-1285.
10. Montgomery SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharm Med. 1980;1:189-192.
11. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kitts C, Mellström B, Linnoila M. Clomipramine treatment of childhood obsessive compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry. 1985;42:977-983.
12. DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatr Ann. 1989;19:97-101.
13. Ananth J, Pecknold JC, Van Den Steen N, Engelsmann F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol Biol Psychiatry. 1981;5:257-262.
14. Foa EB, Steketee G, Kozak MJ, Dugger D. Effects of imipramine on depression and obsessive-compulsive symptoms. Psychiatry Res. 1987;21:123-136.
15. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive compulsive disorder. Psychiatry Res. 1985;14:83-91.
16. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry. 1987;22:667-687.
17. Leonard H, Swedo S, Rapoport JL, Coffey M, Cheslow D. Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull. 1988;24:93-95.
18. Träskman L, Asberg M, Bertilsson L, Cronholm B, Mellström B, Neckers LM, Sjöqvist F, Thorén P, Tybring G. Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol Ther. 1979;26:600-610.
19. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46:36-44.
20. Price LH, Goodman WK, Charney DS, Heninger GR. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry. 1987;144:1059-1061.
21. Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R. Fluvoxamine treatment of obsessive compulsive disorder. Am J Psychiatry. 1988;144:1543-1548.
22. Cottraux J. Predictive factors in the treatment of obsessive-compulsive disorders with fluvoxamine or behaviour therapy. In: Program and abstracts of the Serotonin Symposium; March 29-April 1, 1989; Florence, Italy; p 173.
23. Fontaine R, Chouinard G. Fluoxetine in the long-term maintenance treatment of obsessive compulsive disorder. Psychiatr Ann. 1989;19:88-91.
24. Fontaine R, Chouinard G. Fluoxetine in the treatment of obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:605-608.
25. Turner SM, Jacob RG, Beidel DC, Himmelhoch J. Fluoxetine treatment of obsessive compulsive disorder. J Clin Psychopharmacol. 1985;5:201-212.
26. Fontaine R, Chouinard G, Iny L. An open clinical trial of zimeldine in the treatment of obsessive compulsive disorder. Curr Ther Res. 1985;37:326-332.
27. Kahn RS, Westenberg HGM, Jolles J. Zimelidine treatment of obsessivecompulsive disorder. Acta Psychiatr Scand. 1984;69:259-261.
28. Prasad A. A double blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis. Pharmacopsychiatry. 1984;17:61-62.
29. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessivecompulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985;20:1174-1188.
30. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986;32:313-334.
31. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry. 1981;38:1160-1180.
32. Heninger GR, Charney DS. Mechanism of action of antidepressant treatments: implications for the etiology and treatment of depressive disorders. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:535-544.
33. Blier P, deMontigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol. 1987;7:24S-35S.
34. Peroutka SJ, Snyder SH. Chronic antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science. 1980;210:88-90.
35. Hyttel J, Overo KF, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology. 1984;83:20-27.
36. Ogren SO, Fuxe K, Agnati L. The importance of brain serotonergic receptor mechanisms for the action of antidepressant drugs. Pharmacopsychiatry. 1985;18:209-213.
37. Bradford LD, Schipper J. Biochemical effects in rats after long term treatment with fluvoxamine and clovoxamine: postsynaptic changes. In: Proceedings of the Society for Neuroscience Annual Meeting; October 20-25, 1985; Dallas, Tex. Abstract 224.6.
38. Pawlowski L, Melzacka M. Inhibition of head twitch response to quipazine in rats by chronic amitriptyline but not fluvoxamine or citalopram. Psychopharmacology. 1986;88:279-284.
39. Stolz JF, Marsden CA, Middlemiss DN. Effect of chronic antidepressant treatment and subsequent withdrawal on [3H]-hydroxytryptamine and [3H]spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour. Psychopharmacology. 1983;80:150-155.
40. Price LH, Charney DS, Delgado PL, Anderson GM, Heninger GR. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry. 1986;46:625-631.
41. Delgado PL, Charney DS, Price LH, Goodman WK, Aghajanian GK, Landis H, Heninger GR. Behavioral effects of acute tryptophan depletion in depressed and obsessive compulsive disorder (OCD) patients. In: Proceedings of the Society for Neuroscience Annual Meeting; November 13-18, 1988; Toronto, Canada. Abstract 390.20.
42. Goodman WK, Price LH, Woods SW, Charney DS. Pharmacologic challenges in obsessive compulsive disorder. In: Zohar J, Insel TR, eds. Psychobiology of Obsessive Compulsive Disorder. New York, NY: Springer-Verlag NY Inc. In press.
43. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988;45:167-172.
44. Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine in obsessive-compulsive disorder. Arch Gen Psychiatry. 1989;46:23-28.
45. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol. 1987;7:36S-43S.
46. Leonard BE. Pharmacological effects of serotonin reuptake inhibitors. J Clin Psychiatry. 1988;49:12-17.
47. Hyttel J. Serotonin uptake inhibitors. In: Program and abstracts of the Serotonin Symposium; March 29-April 1, 1989; Florence, Italy. Abstract, p 6.
48. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC; National Institute of Mental Health; 1976. US Dept of Health, Education, and Welfare publication 76-338.
49. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
50. Steketee G, Foa EB, Grayson JB. Recent advances in the behavioral treatment of obsessive-compulsives. Arch Gen Psychiatry. 1982;39:1365-1371.
51. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
52. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry. 1989;46:1012-1016.
53. Goodman WK, Charney DS. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. J Clin Psychiatry. 1985;46:6-22.
54. Brotman AW, Falk WE, Gelenberg A. Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1031-1040.
55. Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants: blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry. 1985;142:155-162.
56. Insel TR, Zohar J. Psychopharmacologic approaches to obsessive-compulsive disorder. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1205-1210.
57. Krystal JH, Goodman WK, Woods SW, Charney DS. Anxiety disorders. In: Lazare A, ed. Outpatient Psychiatry, Diagnosis and Treatment. 2nd ed. New York, NY: Williams & Wilkins; 1989:416-454.
58. Gore CP, Beaumont G. Aspects of a controlled comparative trial of clomipramine (Anafranil), imipramine (Tofranil), electroconvulsive therapy and a placebo. J Pharmacol Clin. 1974;1:237-240.
59. Kampman R, Nummikko-Pelkonen A, Kuha S. Tricyclic antidepressants in the treatment of depressions: a double-blind clinical comparison of clomipramine (Anafranil) and amitriptyline. Acta Psychiatr Scand. 1978;58:142-148.
60. Wolfersdorf M, Binz U, Wendt G, Metzger R, Hole G. Double-blind study of oxaprotiline versus clomipramine in the treatment of depressive inpatients. Neuropsychobiology. 1987;17:41-48.
61. Montejo-Iglesias ML, Ramos-Brieva JA. Therapeutic effect of maprotiline and chlorimipramine: controlled study. Neuropsychobiology. 1988;19:20-24.
62. Åberg-Wistedt A, Ross SB, Jostell KG, Sjöquist B. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a norepinephrine uptake inhibitor, in endogenous depression: clinical and biochemical findings. In: Usdin E, Åaberg M, Bertilsson L, Sjöquist F, eds. Frontiers in Biochemical and Pharmacological Research in Depression. New York, NY: Raven Press; 1984:439-447.
63. d'Elia G, Hällström T, Nyström C, Ottosson JO. Zimelidine vs maprotiline in depressed outpatients: a preliminary report. Acta Psychiatr Scand. 1981;63(S90):225-235.
64. Emrich HM, Berger M, Riemann D, von Zerssen D. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry. 1987;20:60-63.
65. Johnston DG, Troyer IE, Whitsett SF. Clomipramine treatment of agoraphobic women: an eight-week controlled trial. Arch Gen Psychiatry. 1988;45:453-459.
66. Cassano GB, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, McNair DM. Clomipramine for panic disorder, I: the first 10 weeks of a longterm comparison with imipramine. J Affective Disord. 1988;14:123-127.
67. Den Boer JA, Westenberg GM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol. 1988;3:59-74.
68. Lydiard RB. Preliminary results of an open, fixed-dose study of desipramine in panic disorder. Psychopharmacol Bull. 1987;23:139-140.
69. Modigh K. Antidepressant drugs in anxiety disorders. Acta Psychiatr Scand. 1987;76(suppl 335):57-71.
70. Insel TR, Murphy DL, Cohen RM, Alterman I, Kitts C, Linnoila M. Obsessive-compulsive disorder: a double blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983;40:605-612.
71. Jenike MA, Surman OS, Cassem NH, Zusky P, Anderson WH. Monoamine oxidase inhibitors in obsessive-compulsive disorder. J Clin Psychiatry. 1983;144:131-132.
72. Tollefson G. Alprazolam in the treatment of obsessive symptoms. J Clin Psychopharmacol. 1985;5:39-42.
73. Chaput Y, de Montigny C, Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1986;333:342-345.
74. Blier P, de Montigny C. Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience. 1985;16:949-955.
75. Murphy DL. Serotonin neurochemistry: a commentary on some of its quandaries. Neurochem Int. 1986;8:161-163.
76. Potter WZ, Scheinin M, Golden RN, Rudorfer MV, Cowdry RW, Calil HM, Ross RJ, Linnoila M. Selective antidepressants and cerebrospinal fluid: lack of specificity on norepinephrine and serotonin metabolites. Arch Gen Psychiatry. 1985;42:1171-1177.
77. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain, I: serotonin-1 receptors. Brain Res. 1985;346:205-230.
78. Pazos A, Cortés, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain, II: serotonin-2 receptors. Brain Res. 1985;346:231-249.
79. Molliver ME. Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol. 1987;7:3S-23S.
80. Baumgarten HG, Lachenmayer L. Anatomical features and physiological properties of central serotonin neurons. Pharmacopsychiatry. 1985;18:180-187.
81. Schotte A, Maloteaux JM, Laduron PM. Characterization and regional distribution of serotonin S2 receptors in human brain. Brain Res. 1983;276:231-235.
82. Peroutka SJ. Serotonin receptors. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:303-311.
83. Richardson BP, Engel G. The pharmacology and function of 5-HT3 receptors. Trends Neurosci. September 1986:424-428.
84. Peroutka SJ, Switzer JA, Hamik A. Identification of 5-hydroxytryptamine1d binding sites in human brain membranes. Synapse. 1989;3:61-66.
85. Backus LI, Sharp T, Grahame-Smith DG. Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1a receptors. In: Program and abstracts of the Serotonin Symposium; March 29-April 1, 1989; Florence, Italy. Abstract, p 40.
86. Herrick-Davis K, Titeler M. Detection and characterization of the serotonin 5-HT1d receptor in rat and human brain. J Neurochem. 1988;50:1624-1631.
87. Waeber C, Schoeffter P, Palacios JM, Hoyer D. Molecular pharmacology of 5-HT1d recognition sites: radioligand binding studies in human, pig and calf brain membranes. Naunyn Schmiedebergs Arch Pharmacol. 1988;337:595-601.
88. Waeber C, Dietl MM, Hoyer D, Probst A, Palacios JM. Visualization of a novel serotonin recognition site (5-HT1d) in the human brain by autoradiography. Neurosci Lett. 1988;88:11-16.
89. Baxter LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry. 1987;44:211-218.
90. Nordahl TE, Benkelfat C, Semple WE, Gross M, King AC, Cohen RM. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology. 1989;2:23-28.
91. Luxenberg JS, Swedo SE, Flament MF, Friedland RP, Rapoport J, Rapoport SI. Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. Am J Psychiatry. 1988;145:1089-1093.
92. Rapoport JL, Wise SP. Obsessive-compulsive disorder: evidence for basal ganglia dysfunction. Psychopharmacol Bull. 1988;24:380-384.
93. Modell JG, Mountz JM, Curtis GC, Greden JF. Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. J Neuropsychiatry. 1989;1:27-36.
94. Hervé D, Pickel VM, Joh TH, Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 1987;435:71-83.
95. DeSimoni MG, Dal Toso G, Fodritto F, Sokola A, Algeri S. Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res. 1987;411:81-88.
96. Delini-Stula A, Vassout A. Modulation of dopamine-mediated behavioural responses by antidepressants: effects of single and repeated treatment. Eur J Pharmacol. 1979;58:443-451.
97. Yamaguchi K, Nabeshima T, Kameyama T. Potentiation of phencyclidine-induced dopamine-dependent behaviors in rats after pretreatments with serotonin-depletors. J Pharmacobiodyn. 1986;9:479-489.
98. Crespi F, Martin KF, Marsden CA. Simultaneous in vivo voltammetric measurement of striatal extracellular DOPAC and 5-HIAA levels: effect of electrical stimulation of DA and 5-HT neuronal pathways. Neurosci Lett. 1988;90:285-291.
99. Gately PF, Poon SL, Segal DA, Geyer MA. Depletion of brain serotonin by 5,7-dihydroxytryptamine alters the response to amphetamine and the habituation of locomotor activity in rats. Psychopharmacology. 1985;87:400-405.
100. Korsgaard S, Gerlach J, Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol. 1985;118:245-252.
101. Pitman RK. Animal models of compulsive behavior. Biol Psychiatry. 1989;26:189-198.
102. Jelliffe SE. Psychopathology of Forced Movements in Oculogyric Crises. Washington, DC: Nervous and Mental Disease Publishing Co; 1932.
103. Jenike MA. Theories of etiology. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive Compulsive Disorders: Theory and Management. Littleton, Mass: John Wright-PSG Inc; 1986:11-21.
104. Pitman RK, Green RC, Jenike MA, Mesulam MM. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am J Psychiatry. 1987;144:1166-1171.
105. Pauls DL, Towbin KE, Leckman JF, Zahner GEP, Cohen DJ. Gilles de la Tourette's syndrome and obsessive-compulsive disorder: evidence supporting a genetic relationship. Arch Gen Psychiatry. 1986;43:1180-1182.
106. Robertson MM. The Gilles de la Tourette Syndrome: the current status. Br J Psychiatry. 1989;154:147-169.
107. Rakic P, Goldman-Rakic PS, Gallager D. Quantitative autoradiography of major neurotransmitter receptors in the monkey striate and extrastriate cortex. J Neurosci. 1988;8:3670-3690.
108. Rebec GV, Curtis SD. Reciprocal zones of excitation and inhibition in the neostriatum. Synapse. 1988;2:633-635.
109. Cohen DJ, Shaywitz BA, Caparulo B, Young G, Bowers MB Jr. Chronic, multiple tics of Gilles de la Tourette's disease: CSF acid monoamine metabolites after probenecid administration. Arch Gen Psychiatry. 1978;35:245-250.
110. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DM, Heninger GR. Neuroleptic addition in fluvoxamine-refractory OCD. In: Proceedings of the 1989 Annual Meeting of the American Psychiatric Association; NR350, p 189.
111. Sulser F, Gillespie DD, Mishra R, Manier DH. Desensitization by antidepressants of central norepinephrine receptor systems coupled to adenylate cyclase. Ann NY Acad Sci. 1984;430:91-101.
112. Byerley WF, McConnell EJ, McCabe RT, Dawson TM, Grosser BI, Wamsley JK. Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology. 1988;94:141-143.
113. Byerley WF, McConnell EJ, McCabe RT, Dawson TM, Grosser BI, Wamsley JK. Chronic administration of sertraline, a selective serotonin uptake inhibitor, decreased the density of β-adrenergic receptors in rat frontoparietal cortex. Brain Res. 1987;421:377-381.
114. Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology. 1987;93:308-313.
115. Gorman JM, Liebowitz MR, Fyer AJ, Dillon D, Davies SO, Stein J, Klein DF. Lactate infusions in obsessive-compulsive disorder. Am J Psychiatry. 1985;142:864-866.
116. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry. 1987;144:1030-1036.
117. Duncan GE, Paul IA, Powell KR, Fassberg JB, Stumpf WE, Breese GR. Neuroanatomically selective down-regulation of beta adrenergic receptors by chronic imipramine treatment: relationships to the topography of [3H] imipramine and [3H] desipramine binding sites. J Pharmacol Exp Ther. 1989;248:470-477.
118. Schmidt CJ, Lovenberg W. In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat. Neurosci Lett. 1985;59:9-14.
119. Brooks WJ, Jarvis MF, Wagner GC. Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker. J Neural Transm. 1988;71:85-90.
120. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther. 1987;240:1-7.
121. Swedo SE, Rapoport JL, Cheslow DL, Leonard HL, Ayoub EM, Hosier DM, Wald ER. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry. 1989;146:246-249.
122. Laplane D, Widlocher D, Pillon B, Baulac M, Binoux F. Comportement compulsif d'sallure obsessionnelle par nécrose circonscrite bilatérale pallido-striatale: Encéphalopathie par piqûre de quêpe. Rev Neurol. 1981;137:269-276.
123. Johnson J, Lucey PA. Encephalitis lethargica, a contemporary cause of catatonic stupor: a report of two cases. Br J Psychiatry. 1987;151:550-552.